Latest News
Isodiol International to Acquire Bradley´s Bioscience; Expands into Vaping, THC Additive Industries
Monday 13 November 2017

13 November 2017 - Canadian pharmaceutical and wellness products developer Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) is entering into the vaping industry by signing a letter of intent to acquire hemp oil and nicotine e-liquids manufacturer and distributer Bradley's Bioscience Inc., the company said.

Terms of the deal were not disclosed.

Bradley's Bioscience entered the vaping market with its nicotine e-liquids, created to serve as an innovative reduced-risk product compared to traditional cigarettes.

Through this agreement, the company will expand its product offerings to include non-CBD lines, hemp oil vaping e-liquids, THC additives, and organic men's grooming products.

Bradley's Bioscience manufactures more than 500+ nicotine products across several brands; all of which are compliant with current FDA regulations and approved for sale in both the United States and internationally.

Isodiol International is in pharmaceutical grade phytochemical compounds and a specialsit in the manufacturing and development of phytoceutical consumer products.

Isodiol claims many firsts for the cannabis industry, including commercialisation of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

The company's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Date Published: 13/11/2017
Target: Bradley, ´s Bioscience
Country: USA
Sector: Consumer Products
Type: Corporate acquisition
Status: Agreed
Buyer: Isodiol International
Terms of the deal were not disclosed